(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 239.42% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.8%.
Nuvation Bio's revenue in 2024 is $2,162,000.On average, 2 Wall Street analysts forecast NUVB's revenue for 2024 to be $734,051,591, with the lowest NUVB revenue forecast at $727,656,827, and the highest NUVB revenue forecast at $740,446,355. On average, 1 Wall Street analysts forecast NUVB's revenue for 2025 to be $1,082,061,378, with the lowest NUVB revenue forecast at $1,082,061,378, and the highest NUVB revenue forecast at $1,082,061,378.
In 2026, NUVB is forecast to generate $34,457,680,830 in revenue, with the lowest revenue forecast at $34,457,680,830 and the highest revenue forecast at $34,457,680,830.